Company intelligence / Profile preview

New River Management V

Radford, Virginia, United States

Ownership: Private
Development stage: Other

Overview

New River Management V is a life sciences-focused venture capital fund managed by Third Security, LLC, an investment firm led by Randal J. Kirk. Established in 2007, the fund served as a primary investment vehicle for Kirk's activities in the biotechnology sector following the sale of New River Pharmaceuticals to Shire. The fund held significant positions in several prominent biotech companies, including Halozyme Therapeutics, Intrexon Corporation (now Precigen), and Clinical Data. New River Management V was part of a series of 'New River' funds and was liquidated in 2017 after completing its investment lifecycle.

Industry: Investors

Beyond the preview

Go deeper on New River Management V.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New River Management V.

Explore the full profile